$Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)$

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

Update: 2025-03-31

Description

Professor Amar U. Kishan (Department of Radiation Oncology, University of California, Los Angeles, CA, USA) discusses his paper on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA): An Individual Patient Data Meta-Analysis of Randomised Trials in the MARCAP Consortium.

Read the full article:

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00034-8/fulltext?dgcid=buzzsprout_icw_podcast_generic_lanonc

Tell us what you thought about this episode

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments

In Channel

Linda Bi, Ruchit Patel, Chloe Gui, Farshad Nassiri, and Matija Snuderl on TERT expression and TERT promoter mutations in meningiomas

2025-09-0214:22

Jinming Li on patterns in genomic mutations among patients with early-onset colorectal cancer

2025-07-2807:36

Abdalla Awidi on cancer control in the Middle East

2025-06-1108:22

ASCO 2025 Debrief

2025-06-1114:45

Caroline Robert on treatments for patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN trial)

2025-05-2810:45

Richard Bryant on transperineal vs transrectal biopsy for prostate cancer

2025-04-3018:02

$Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)$

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

2025-03-3107:33

Ariana Znaor on cancer surveillance in the Eastern Mediterranean region

2025-03-0320:03

Ian Tannock on Common Sense Oncology principles for phase 3 randomised clinical trials

2025-02-0318:03

Yannick Romero on the changing landscape of national cancer control plans

2025-01-0224:40

M Saiful Huq and Mostafa Aziz Sumon on the series Cancer Care in South Asian Association for Regional Cooperation (SAARC) Countries

2024-12-0222:15

$Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma$

Steven Horwitz on valemetostat for relapsed or refractory T-cell lymphoma

2024-10-3015:07

Zachary Zumsteg on early phase trial design for novel drug-radiotherapy combination

2024-09-3017:21

May Abdel-Wahab and Andrew Scott on The Lancet Oncology Commission on Radiotherapy and Theranostics

2024-09-3040:45

Kanwal Raghav on trastuzumab deruxtecan in HER2-positive advanced colorectal cancer (DESTINY-CRC02)

2024-08-2713:22

Emmy Boerrigter on dose selection of novel anticancer drugs

2024-07-2911:41

Hisham Mehanna and Sue Yom on head and neck cancer consensus recommendations

2024-06-2436:56

Garth Strohbehn and Katie Lichter on the environmental impact of cancer treatment

2024-05-2824:08

James Shultz, Ana Patricia Ortiz, and Leticia Nogueira on cancer and compounding disasters in the Caribbean

2024-04-2935:05

Bernardo Goulart on correlations of endpoints in lung cancer immunotherapy trials

2024-04-0811:22

00:00

$Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)$

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

#box-pro-ellipsis-175884469510841{-webkit-line-clamp:2;}Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)

The Lancet Group

Professor Amar U. Kishan on HYpofractionateD RAdiotherapy for Prostate Cancer (HYDRA)